山西医科大学学报2025，Vol.56Issue(1)：15-19,5.DOI:10.13753/j.issn.1007-6611.2025.01.003
红树林来源放线菌Kribbella karoonensis A01098的次级代谢产物的成分及其抗肿瘤活性
Secondary metabolites and their in vitro antitumor activities of Actinobacteria Kribbella karoonensis A01098 derived from mangrove
摘要
Abstract
Objective To investigate the chemical constituents and in vitro antitumor activities of secondary metabolites derived from the mangrove-associated Actinobacteria Kribbella karoonensis A01098.Methods The liquid fermentation products of Kribbella karoo-nensis A01098 were separated and purified by silica gel chromatography and Sephadex LH-20 gel column chromatography.The charac-terization of the isolated compounds was performed using nuclear magnetic resonance(NMR)and mass spectrometry(MS)to identify their structures.The inhibitory effects of the compounds on the proliferation of human liver cancer cells(HepG2)and cervical cancer cells(HeLa)were evaluated using the methylthiazolyldiphenyl-tetrazolium bromide(MTT)assay.Results Totally five compounds were isolated from the ethyl acetate fraction of the liquid fermentation products of Kribbella karoonensis A01098,and identified as cyclo-(L-proline-glycine),cyclo-(trans-4-hydroxy-L-proline-L-leucine),cyclo-(cis-4-proline-D-proline-L-phenylalanine),cyclo-(trans-4-hydroxy-L-proline-L-phenylalanine),and 2-aminobenzoic acid.The half-maximal inhibitory concentrations(IC50)of five compounds against HepG2 and HeLa cells were all higher than 50 μmol/L.Conclusion Five compounds,four cyclic dipeptides and one anthra-nillic acid,are isolated and identified from Kribbella karoonensis for the first time.The five compounds have no significant inhibitory effects on the proliferation of HeLa and HepG2 cells.关键词
放线菌/Kribbella karoonensis/次级代谢产物/结构鉴定/环二肽/肿瘤细胞/增殖抑制Key words
actinobacteria/Kribbella karoonensis/secondary metabolites/structural identification/cyclic dipeptides/tumor cells/proliferation inhibition分类
药学引用本文复制引用
郭娜燕,罗彩林,陈若海,邱丹缨..红树林来源放线菌Kribbella karoonensis A01098的次级代谢产物的成分及其抗肿瘤活性[J].山西医科大学学报,2025,56(1):15-19,5.基金项目
泉州市医疗卫生领域指导性科技计划项目(2023N016S) （2023N016S）
